Comparative study of tumor angiogenesis and immunohistochemistry for p53, c-ErbB2, c-myc and EGFr as prognostic factors in gastric cancer J. Sanz-Ortega1, S.M. Steinberg2, E. Moro1, M. Saez1, J.A. Lopez1, E. Sierra1, J. Sanz-Esponera1 and M.J. Merino2 1Hospital Universitario "San Carlos", Madrid, Spain and 2Laboratory of Pathology, National Cancer Institute, Bethesda, MD, USA Offprint requests to: Julian Sanz Ortega, MD, Departamento de Anatomía Patológica, Hospital Universitario "San Carlos", Martin Lagos s.n., Madrid 28040, Spain. Fax: 34-913303032. e-mail: jsanz@hcsc.insalud.es
Summary. Gastric
cancer (GC) continues to be a highly aggressive malignancy with
poor prognosis and low survival rates. The survival of patients
with GC depends mainly on the stage of the disease, with early
GC having a 5 year survival of 90-100% and advanced tumors a 5
year survival of 15-25%. The role of other prognostic factors
in these tumors is still under investigation. 28 gastric dysplasia,
45 Early GC and 98 Advanced Gastric Cancers were evaluated for
expression of the oncogenes p53, c-ErbB2, c-myc and the EGFr in
paraffin-embedded material utilizing Avidin-Biotin immunohistochemistry
techniques. In 34 cases of GC microvessel density (MVD) was determined
in CD34 stained sections. Statistical correlations with stage,
histologic type, differentiation degree, location, size, ploidy
patterns and overall survival were done. The Mantel-Cox test was
performed to evaluate which factors had an independent prognostic
value.
Key words: Angiogenesis,
p53, Gastric cancer, Prognosis |